Document
type: Class

RDF description of Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study - http://irises.uniss.it/resource/item/355306
rights: termsOfUse
date: 2026-08-25T01:16:17
publisher: Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study
type: Document

Academic Article
type: Class

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

Article
type: Class

315184343
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study

Information Content Entity
type: Class

Inglese
type: Language

Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study
type: Continuant
type: Entity
language: Inglese
type: Generically Dependent Continuant
type: Thing
type: Article
type: Academic Article
related by: 315184343
type: Document
type: Information Content Entity
most specific type: Academic Article